---
schema_version: "secwatch.filing_event.v1"
accession: "0001434647-25-000009"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:14:19.787865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra Q3 net loss narrows to $0.5M; revenue jumps to $26.1M on MIPLYFFA sales

## Summary
- Q3 net revenue $26.1M (vs $3.7M YoY), with MIPLYFFA contributing $22.4M.
- Net loss $(0.5)M or $(0.01) per share vs $(33.2)M or $(0.69) per share in Q3 2024.
- MIPLYFFA prescription enrollment forms total 137 since launch; market access 66% of covered lives.
- Cash and securities $230.4M as of Sep 30, 2025; company believes sufficient to fund operations.
- Arimoclomol EMA application validated under review; celiprolol Phase 3 trial enrolled 44 patients.

## SEC filing metadata
- accession: 0001434647-25-000009
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143464725000009/0001434647-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143464725000009/zvra-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001434647-25-000009
- JSON: https://secwatch.observer/filing/0001434647-25-000009.json
- Plain text: https://secwatch.observer/filing/0001434647-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.